



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

1 March 2024

Dear registered shareholder(s),

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Genscript Biotech Corporation (the “**Company**”) is writing to inform you that, effective from 1 March 2024, the Company will disseminate the future corporate communications (the “**Corporate Communications**”) electronically and only send Corporate Communications in printed form to you upon your request. Corporate Communications mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at <https://www.genscript.com/announcements-circulars.html> and the HKExnews website at www.hkexnews.hk in place of printed copies. The Company will not send a notice of publication of the Corporate Communications on the website of the Company and HKExnews to you. You are encouraged to proactively monitor the availability of all future Corporate Communications on the websites and access the Corporate Communications via the websites above by yourselves.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications^(Note), the Company recommends you to provide your email address by scanning your personalized QR code printed on the reply form on the reverse side (the “**Reply Form**”). Alternatively, you may sign and return the Reply Form to the Company’s Hong Kong share registrar (the “**Share Registrar**”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, the Company will send the Actionable Corporate Communications^(Note) in printed form in future.

If you wish to receive the future Corporate Communications in printed form, please complete and return the Reply Form to the Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, or send an email to genscript.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the Share Registrar at (852)2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully,
By order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.

各位登記股東：

以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則（「**上市規則**」）第 2.07A 條，金斯瑞生物科技股份有限公司（「**本公司**」）謹此通知閣下，自 2024 年 3 月 1 日生效，本公司將以電子方式發布日後的公司通訊（「**公司通訊**」），並僅應閣下要求向閣下寄發印刷本形式的公司通訊。公司通訊是指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件，包括但不限於(a) 董事報告、年度帳目以及審計報告副本以及（如適用）財務摘要報告；(b) 中期報告及（如適用）其中期報告摘要；(c) 會議通知；(d) 上市文件；(e) 通函和 (f) 代表委任表格。

請注意，所有未來公司通訊的英文版和中文版將在本公司網站 <https://www.genscript.com.cn/announcements-circulars.html> 和披露易網站 www.hkexnews.hk 上提供，以代替印刷本。本公司不會向閣下發出公司通訊登載在本公司網站和披露易網站的登載通知。本公司鼓勵閣下主動留意網站上所有日後的公司通訊的登載情況，並通過以上網站自行瀏覽公司通訊。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊^(附註)，本公司建議閣下透過掃描本函背頁之回條（「**回條**」）上列印的閣下專屬二維碼來提供閣下的電子郵件地址。或者，閣下也可以簽署回條並交回本公司的香港股份過戶登記處（「**股份過戶處**」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果本公司沒有收到閣下的有效電子郵件地址，直至股份過戶處收到閣下有效的電子郵件地址前，本公司未來將以印刷本形式發送可供採取行動的公司通訊^(附註)。

若閣下希望收取日後公司通訊之印刷版，請填妥回條並交回股份過戶處香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓，或發送電子郵件至 genscript.ecom@computershare.com.hk，並註明閣下的姓名、地址以及收取公司通訊之印刷版的要求。請注意，收取未來公司通訊印刷版之指示由收悉閣下指示當日起計一年內有效，此後將過期。

如閣下對本函件有任何疑問，請於辦公時間星期一至五（香港公眾假期除外）上午 9 時正至下午 6 時正（香港時間）其間致電股份過戶處 (852)2862 8688 查詢。

承董事會命
金斯瑞生物科技股份有限公司
孟建革
董事長及執行董事
謹啟

二零二四年三月一日

附註：可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

*For identification purposes only 僅供識別

